The speculative corner.

Small Nordic companies trading below DKK 3 a share, often with little revenue and a short cash runway. We give each one two separate ratings.

High risk. Most stocks at this price lose money, dilute their shareholders and can go to zero. A high asymmetry rating is not a recommendation; it only says the possible upside is large relative to what we think could go wrong. Not investment advice.

Two ratings, side by side

Bjarvik score · 1–100

The normal Bjarvik model: business, price and cracks. It measures quality, and penny stocks usually score low.

Asymmetry · 1–10

A separate speculative rating of potential against risk: market value, upcoming catalysts, partners, cash runway and how close the price is to its low.

The list

Sorted by asymmetry. Price and market value in DKK; runway in months; dilution is the growth in share count over the last 12 months.

Penny stocks under DKK 3, sorted by asymmetry. Select a column heading to sort.
CompanyPriceMkt cap (m)AsymmetryBjarvikRunwayDilutionNext catalyst
Pricer
Sweden · Tech hardware & optics		2.6041866299+0%22 Oct 2026Q3 2026 report: how much of the Carrefour decline comes through, and whether the gross margin of approx. 28% holds
OssDsign
Sweden · Pharma & medtech		2.2925356539+0%3 Nov 2026Q3 report: shows whether Catalyst sales turn after the rebuilding of the sales force
Spanish Mountain Gold
Canada · Commodities & uranium		1.4275055916+17%26 Nov 2026Q3 report (estimated date) – cash and burn
District Metals
Canada · Commodities & uranium		2.0939955538+29%Q4 2026New Swedish government after the election 13/9-2026 - its line on uranium mining, alum shale and the removed municipal veto
Cantargia
Sweden · Pharma & medtech		0.9626255427+33%25 Nov 2026Q3 report: cash after the share issue and update on the MDS/AML study
KebNi
Sweden · Defence, aerospace & space		0.5117555320+26%16 Feb 2027Annual accounts 2026: first year after the issue and the doubling of IMU capacity
Precise Biometrics
Sweden · Software, cloud & internet		0.349255041+247%13 Nov 2026Q3 2026 report: first quarter with Fingerprint Cards consolidated, cash after the issue and synergy status
Sintana Energy
Canada · Oil & gas		1.6089754919+47%End of 2026High-impact exploration well on PEL 90 (Namibia), Sintana fully funded
Elicera Therapeutics
Sweden · Pharma & medtech		1.8411754932+37%27 Nov 2026Q3 report and updated follow-up on durability of responders in phase 1
Mogotes Metals
Canada · Commodities & uranium		2.181,32354712+82%The 2026–27 season (southern summer)Up to 20,000 m of drilling at Filo Sur: expansion of Albor and Cruz del Sur and first porphyry tests at Luz del Sol-Cuenca and Meseta
CanAlaska
Canada · Commodities & uranium		1.4431854618+21%Q4 2026Assay results from the 2026 summer drilling at West McArthur (step-outs along the C10S corridor from Pike Zone; the programme ended in September)
PetroTal
Canada · Oil & gas		2.602,39345999+1%13 Nov 2026Q3 2026 report (estimated date) – production, cash and possible dividend signal
Context Therapeutics
United States · Pharma & medtech		1.9818245814+8%4 Nov 2026Q3 report: confirmation of first patient in CT-202 and cash
Greenlane Renewables
Canada · Machinery & automation		0.8613745717+2%12 Nov 2026Q3 2026 results with order backlog and order intake
Xtract One
Canada · Tech hardware & optics		2.3260445729+13%FY2027Installation of C$27.2m in agreements awaiting installation – must be converted into revenue and subscriptions
Senzime
Sweden · Pharma & medtech		1.7928145715+0%Q4 2026 (report approx. Feb. 2027)The company's target of profitability in Q4 2026
Kongsberg Automotive
Norway · Autos & parts		1.381,27945620+0%Jun 2028EUR 110m bond matures - possible early refinancing at a lower rate; target of 6.5% EBIT margin
Mereo BioPharma
United States · Pharma & medtech		2.6542345616+2%9 Nov 2026Q3 report: cash and status of Sentynl and regulatory dialogue
aTyr Pharma
United States · Pharma & medtech		2.0019645525+17%5 Nov 2026Q3 report: cash, new CFO and financing plan for phase 3
Defense Metals
Canada · Commodities & uranium		0.602384557+36%2026-11-27 (estimated)Q2 FY2027 results (to 30/9) – cash and status of the DFS
Stenocare
Denmark · Pharma & medtech		0.903945417+13%No date (decree sent to the Conseil d'État 2/7-2026)French decree on price and reimbursement for medical cannabis is adopted, so ASTRUM 10-10 can apply for access
Lahontan Gold
Canada · Commodities & uranium		1.7676345313+56%25 Nov 2026Q3 report (estimated date) – cash and burn
ShaMaran Petroleum
Norway · Oil & gas		0.992,8864539+1%9 Nov 2026Q3 2026 results: status of shutdown/restart of Atrush and Sarsang, cash and PSC payments
Cassiar Gold
Canada · Commodities & uranium		2.2135645311+13%Q4 2026Assay results from the 2026 drilling campaign (7,400 of 10,000 m drilled at Taurus and Newcoast as of 17/9)
Gunnison Copper
Canada · Commodities & uranium		2.141,08045213+40%13 Nov 2026Q3 2026 results (estimated) – first quarter with commercial production at Johnson Camp
Ferroamp
Sweden · Grid & electrical equipment		1.631904511+0%2026-11-06 (stockanalysis estimates 2026-11-09)Q3 report: does sales hold the Q2 level (60m), and is EBITDA positive per month?
Brunswick Exploration
Canada · Commodities & uranium		1.143214518+23%6 Nov 2026Q3 results (estimated date) – cash after the summer programme
Oroco Resource
Canada · Commodities & uranium		2.146964508+29%Q4 2026 (ongoing)Remaining phase 2 analyses from South Zone and start of drilling in Pillar Zone
Bluelake Mineral
Sweden · Commodities & uranium		0.8818044915+82%18 Nov 2026Q3 report (estimated date): cash after the issue, drilling results at Joma/Gjersvik and timeline for the PFS
Laramide Resources
Canada · Commodities & uranium		2.146254498+14%13 Nov 2026Q3 report (estimated date) – cash after the placement
Elliptic Labs
Norway · Software, cloud & internet		2.2728844812+20%19 Nov 2026Q3 2026 report: does revenue show that the laptop contracts exceed the minimum thresholds?
Nykode
Norway · Pharma & medtech		2.3898444828+20%25 Nov 2026Q3 report: update on recruitment in Abili-T and booking of the lost tax case
Midsummer
Sweden · Chip equipment		0.8950644825+61%2026 (ongoing)Delivery and revenue recognition of most of the SEK 236m order
Innoviz
United States · Autos & parts		2.3968944815+40%11 Nov 2026Q3 report: NRE payments, progress towards guidance (67–73m USD) and new programmes
IRLAB Therapeutics
Sweden · Pharma & medtech		1.1818144717+61%13 Nov 2026Q3 report
Viaplay
Sweden · Software, cloud & internet		0.763,63544720+-1%Q4 2026Completion of the sale of Holland (142 m EUR) – net debt falls about 30%
Crunchfish
Sweden · Software, cloud & internet		1.451204469+11%12 Nov 2026Q3 report: cash, any strategic investor and status of NPCI, GCash and Mercury
Dicot Pharma
Sweden · Pharma & medtech		0.1550644630+72%Q4 2026Decision on the EU application (CTA) for phase 2b
Sun Summit Minerals
Canada · Commodities & uranium		0.6522944610+232%Q4 2026 (ongoing)Assay results from 55 holes (over 16,000 m) on the Creek, Finn and Schmitt zones
F3 Uranium
Canada · Commodities & uranium		0.5635244616+20%Q4 2026Remaining results from the 2026 summer programme (about 4,000 m; the A4 conductor, Broach Lake, JR's south-eastern extension and the Tetra area)
Intrum
Sweden · Financial data & insurance broking		2.026,64544515+2,250%2027Refinancing of new money notes (maturing Dec. 2027) and first exchange notes – test of market access after Chapter 11
Lucara Diamond
Canada · Commodities & uranium		0.781,18944515+94%6 Nov 2026Q3 2026 report (estimated date): diamond prices, stockpile processing and UGP progress
Questerre Energy
Canada · Oil & gas		1.40611445–+3%12 Nov 2026Q3 2026 results: shows whether sales in Brazil have reached the contract minimum, and whether the inventory of 40,000 barrels has been sold
Excellon Resources
Canada · Commodities & uranium		1.586964456+95%13 Nov 2026Q3 2026 report (estimated) – first concentrate sales and cash balance
Emerita Resources
Canada · Commodities & uranium		1.654894454+10%Q4 2026Publication of the PFS for Iberian Belt West (NPV, IRR, capex) - 'in the coming weeks' after extended review
Akobo Minerals
Norway · Commodities & uranium		1.2026944510+7%Q4 2026Vertical shaft reaches first lateral level – target of 50 kg/month (about 5x current)
Initiator Pharma
Sweden · Pharma & medtech		1.359244511+22%20 Nov 2026Q3 report with status of recruitment for the vulvodynia study and cash
Salmon Evolution
Norway · Food, drinks & restaurants		2.281,2804443+17%Q4 2026First harvest from phase 2 (Indre Harøy) and handover of the last 8 of 12 growth tanks during 2026
Southern Silver
Canada · Commodities & uranium		2.379944434+26%Q4 2026Updated resource estimate with Puro Corazon (planned for Q3 2026)
Diamyd Medical
Sweden · Pharma & medtech		0.6910444320+37%Not disclosed (the company only reports on the final outcome)Outcome of strategic review: sale/out-licensing of retogatein, sale of the Umeå factory or a transaction with one of the shortlisted counterparties
Global Atomic
Canada · Commodities & uranium		1.791,0554426+87%13 Nov 2026Q3 results (estimated date) – cash, capex burn and status of DFC conditions
Alzinova
Sweden · Pharma & medtech		0.268944111+200%12 Nov 2026Q3 report
Ascelia Pharma
Sweden · Pharma & medtech		0.54564418+42%5 Nov 2026Q3 report with cash and burn after the savings
DMG Blockchain
Canada · Software, cloud & internet		2.3749243933+2%18 Dec 2026Annual accounts 2025/26 (Q4) with bitcoin holdings and debt
Clavister
Sweden · Software, cloud & internet		2.841,06236825+7%12 Nov 2026Q3 2026 report: do the margin and order intake hold after the record quarter?
Deoleo
Spain · Food, drinks & restaurants		2.641,31736099+0%Q4 2026 – H1 2027The Spanish government's approval or blocking of a foreign takeover (investment screening)
OHLA
Spain · Construction & materials		2.623,64535999+50%Nov 2026Q3 2026 report: whether the margin improvement in construction (7.3% EBITDA margin) holds, and whether the cash flow continues
Mega Uranium
Canada · Commodities & uranium		2.3088535590+4%18 Dec 2026Annual accounts for the financial year to 30/9-2026 (estimated date) – updated portfolio and debt
Sprint Bioscience
Sweden · Pharma & medtech		2.2821735217+41%Not disclosedThe first development milestone from Gilead on TREX1 (part of up to USD 400m)
Oncopeptides
Sweden · Pharma & medtech		1.4460135111+45%5 Nov 2026Q3 report: sales growth, burn and cash (runway)
Touchstone Exploration
Canada · Oil & gas		0.7934835117+69%13 Nov 2026Q3 2026 results (estimated) – first quarter with full compressor effect; status of covenant waiver and going concern
Rekor Systems
United States · Software, cloud & internet		2.4333434910+29%2026-11-12 (estimated)Q3 report: test of the target of positive adjusted EBITDA in H2 2026
Pharol
Other · Financial data & insurance broking		0.67549349212+0%2026–27First investments or new strategy under chairman João Moreira Rato (approved by the ECB on 17/8-2026, mandate to 2028)
Focus Graphite
Canada · Commodities & uranium		1.932133493+39%2026-12-23 (estimated)Annual accounts FY2026 (to 30/9) – cash, going concern and warrant status
BioPorto
Denmark · Pharma & medtech		1.0553734912+30%19 Nov 2026Q3 report: NGAL growth after recall and cash balance
Scandinavian Medical Solutions
Denmark · Pharma & medtech		2.37703471+7%19 Nov 2026Annual report 2025/26: actual EBITDA vs −9 to −13m, inventory value, writedowns and expectations for 2026/27
Premier American Uranium
Canada · Commodities & uranium		1.491423478+108%20 Nov 2026Q3 report (estimated date) – cash after the drilling season
Guanajuato Silver
Canada · Commodities & uranium		1.831,39234612+42%27 Nov 2026Q3 2026 report (estimated date) – margin, cash and AISC after record capex
Medivir
Sweden · Pharma & medtech		1.0666834525+203%5 Nov 2026Q3 report (recruitment in FLEX-HCC and start of OI and Perthes studies)
Verimatrix
France · Software, cloud & internet		2.3420434599+1%Approx. March 2027Annual accounts 2026: does it reach the Anti-Piracy EBITDA target of at least USD 3m, and does revenue return to growth?
Evogene
United States · Pharma & medtech		2.614334413+51%2026-11-19 (approx.)Q3 2026 results: cash burn and any paid ChemPass agreements
HPQ Silicon
Canada · Commodities & uranium		0.632963445+14%2026-11-27 (estimated)Q3 2026 results – shows whether new capital has been raised, and how the HSPI transaction is booked
Tobii
Sweden · Tech hardware & optics		0.7316634311+0%Q4 2026Outcome of strategic review: divestment/partnership in Autosense or capital raise
Acarix
Sweden · Pharma & medtech		0.131673437+8%5 Nov 2026Q3 report: sales in the USA, systems and patches, and cash
Heron Therapeutics
United States · Pharma & medtech		2.0739234336+20%3 Nov 2026Q3 report with terms of the Long Grove licence and update on CINVANTI and the strategic process
AEON Biopharma
United States · Pharma & medtech		1.98983436+614%13 Nov 2026Q3 report with cash and runway after the July issue
Prairie Operating
United States · Oil & gas		2.713063433+330%2026-11-13 (approx.)Q3 2026 results: first quarter under the new minimum production covenant; August production was approx. 27,000 boe/d
Hofseth BioCare
Norway · Food, drinks & restaurants		0.8846334248+27%6 Nov 2026Q3 2026 report: effect of the price increases on ProGo/OmeGo and whether operations are close to EBITDA balance
Smoltek
Sweden · Semiconductors		0.8820934216+32%5 Nov 2026Q3 report: first quarter with the issue money, cash and any customer agreements
PyroGenesis
Canada · Machinery & automation		1.393153411+17%Nov 2026Q3 2026 results (Q3 2025 came in November) – shows whether revenue growth and the lower loss hold, and how liquidity is after the July maturity
Purepoint Uranium
Canada · Commodities & uranium		1.301073416+34%27 Nov 2026Q3 report (estimated date) – cash and financing need
Observe Medical
Norway · Pharma & medtech		0.62863403+605%Q4 2026Target of positive operating cash flow; if not reached, new financing is required (going concern qualification)
PILA PHARMA
Sweden · Pharma & medtech		1.16563409+45%Turn of the year 2026/27Result of part 1: safety and tolerability at high doses plus the first weight data
Danish Aerospace
Denmark · Defence, aerospace & space		2.40463400+75%approx. 2026-11-24Q3 update: liquidity, whether the postponed orders have come in, and whether guidance (18–20m DKK) holds
HydrogenPro
Norway · Grid & electrical equipment		0.324534010+60%13 Nov 2026Q3 report: cash, burn and status of the strategic review
Latecoere
France · Defence, aerospace & space		0.081,03534024+1%Q1 2027 (March)Annual accounts 2026: shows whether the aerostructure loss has turned and whether FCF holds
Volatus Aerospace
Canada · Defence, aerospace & space		2.511,84433938+32%13 Nov 2026Q3 2026 results (estimated date) – shows whether the postponed defence order of approx. 2.6m C$ has been delivered
Capsol Technologies
Norway · Machinery & automation		2.962273393+11%11 Nov 2026Q3 2026 report: liquidity, drawdown on the DNB facility and any capital raise
Ocean GeoLoop
Norway · Machinery & automation		0.65813386+187%5 Nov 2026Q3 report: cash, burn and status of COOL and the new CEO
Photon Energy
Poland · Utilities & power		2.061243386+1%Q4 2026New vote among the bondholders on a joint representative and an independent business review, then a concrete restructuring proposal
SBB
Sweden · Construction & materials		1.833,64733615+5%24 Nov 2026Q3 2026 report: LTV, refinancing of the 13% preferred shares and plan for 2027 maturities
Vantiva
France · Tech hardware & optics		0.5728033599+0%Nov–Dec 2026Move of the listing to Euronext Growth (at the earliest two months after 23/9-2026, requires Euronext's approval)
Sernova
Canada · Pharma & medtech		0.491843350+7%Nov 2026Shareholder meeting and closing of the merger of Seraxis into BetaNova Biotherapeutics (requires 2/3 majority, court and TSX approval); Sernova shareholders get about 50%
K33
Sweden · Financial data & insurance broking		0.012113352+17%26 Nov 2026Q3 2026 report: liquidity, bitcoin holdings and whether the MiCA expansion gives volume
Canaan
United States · Tech hardware & optics		2.271,6973346+97%2026-11-17 (approx.)Q3 2026 results: guidance is only 11–15m USD in revenue; focus on cash and burn
Silver Storm Mining
Canada · Commodities & uranium		2.412,1013333+56%24 Nov 2026Report for the quarter to 30/9/2026 (estimated) – first sales from the oxide and sulphide circuit and new cash balance
Aston Martin
United Kingdom · Autos & parts		2.973,02033210+12%Ongoing from 2026-08 (monthly)Test of the minimum liquidity covenant under the new HPS loan agreement
Desert Control
Norway · Construction & materials		0.2510733212+700%20 Nov 2026Q3 2026 report: first evidence of whether guidance of about USD 2m for 2026 holds
Nel
Norway · Grid & electrical equipment		1.432,57833226+0%latest about December 2026New CEO (Volldal stepped down with six months' notice in June)
Realbotix
Canada · Machinery & automation		1.322913319+7%autumn 2026Launch of new robot line: tabletop model at about USD 12,000 and full size at about USD 55,000
Minesto
Sweden · Grid & electrical equipment		0.762013318+22%Q4 2026 – Q1 2027Capital raise necessary (amount and form unknown)
Ferrexpo
United Kingdom · Commodities & uranium		2.762,86033018+76%Ongoing 2026-2027Resumption of VAT refunds (102 m USD receivable) and return of more pellet lines; a ceasefire in Ukraine would be the big gradual driver
Lifecare
Norway · Pharma & medtech		0.351503299+700%12 Nov 2026Q3 report: cash, burn and update on production
Tullow Oil
United Kingdom · Oil & gas		0.891,35032899+1%Q4 2026 (no fixed date)Agreement with Ghana's government on paying the tax bill of up to USD 393m – determines liquidity
Zenith Energy
Norway · Oil & gas		0.362573272+39%Dec 2026Half-year report at 30/9-2026 (latest end of December) with status on cash, bond maturity and the Daybreak acquisition
Norse Atlantic
Norway · Transport & logistics		0.215813207+1,716%1 Nov 2026The ACMI contract with IndiGo is ending; the last aircraft are returning and must be deployed on own routes (including Europe–Thailand)
Accuray
United States · Pharma & medtech		1.7821224738+19%2026-11-04 (estimated)Q1 FY2027 report: order intake (−55% in Q4), China and margin after the cost programme
Flux Power
United States · Grid & electrical equipment		2.97642431+19%2026-11-12 (approx.)Q1 FY2027 results: revenue, gross margin and liquidity
SunPower
United States · Utilities & power		2.024222433+105%2 Nov 2026General meeting (virtual); possible proposals on reverse split and board
Vistagen
United States · Pharma & medtech		2.03902426+31%12 Nov 2026Q2 FY2027 report: cash at 30/9, burn and any update on the FDA meeting
Lion One Metals
Canada · Commodities & uranium		0.863692423+33%31 Dec 2026Deadline for repayment/refinancing of the Nebari loan (about 31.2 m US$) under the forbearance agreement
VolitionRx
United States · Pharma & medtech		1.70242412+44%12 Nov 2026Q3 report: cash after the Lind prepayment and financing
Episurf
Sweden · Construction & materials		0.0553523858+340%2026-11-01 (planned)Acquisition of five property companies (approx. SEK 505m, binding agreement by 30/9)
Metacon
Sweden · Grid & electrical equipment		0.0814723610+45%4 Nov 2026Q3 2026 report: cash after loan repayment, milestone payments and order book
Patagonia Gold
Canada · Commodities & uranium		1.979272360+0%2026-11 (estimated)Q3 2026 report – first full quarter of ramp-up at Calcatreu (production, sales, debt)
MindMaze Therapeutics
Switzerland · Pharma & medtech		1.192022364+11%Ongoing 2026-27The reimbursement studies SwissNeuroRehab (Switzerland) and REACT-AVC (France) and rollout via Vibra Healthcare in the USA
Hilbert Group
Sweden · Financial data & insurance broking		1.131482342+62%30 Nov 2026Q3 report: fee income, effect of the savings, cash and use of the LDA facility
KALA BIO
United States · Pharma & medtech		2.825523314+6,875%Nov 2026Due diligence on the telehealth acquisition is completed
Hyperscale Data
United States · Software, cloud & internet		1.091842327+7,263%monthly from 2026Monthly status reports on the Michigan AI data centre and start-up of the first 20 MW under the master services agreement
GenSight Biologics
France · Pharma & medtech		0.701632313+46%Q4 2026Meeting with the FDA on the final RECOVER protocol; last patient in the dose study REVISE (December)
Ebusco
Netherlands · Autos & parts		1.353522306+312%Q4 2026 (early)Extraordinary general meeting: change of auditor from EY to CFA and Rhein Holding's seat on the supervisory board
Maisons du Monde
France · Food, drinks & restaurants		1.671,3662298+1,991%Jan–Feb 2027Revenue for 2026 (incl. Christmas trade) - shows whether the decline stops under the new owners
Alligator Bioscience
Sweden · Pharma & medtech		0.01472288+8,000%2026 (no date)Sale or licence of mitazalimab, which the company will try in 2026
Beowulf Mining
Sweden · Commodities & uranium		0.44292281–Dec 2026–Mar 2027ISP decision on the Bacchus investment (review started 10/9, up to 3–6 months)
Ensurge Micropower
Norway · Tech hardware & optics		0.383792283+30%11 Nov 2026Q3 2026 report: cash, financing and customer validation
Cereno Scientific
Sweden · Pharma & medtech		2.658542266+8%4 Nov 2026Q3 report: cash, burn and any financing plan
Hexagon Purus
Norway · Machinery & automation		2.9212422515+13%No date (2026–2027)'Structural measures' for the convertible bonds – decide how much of the company shareholders keep
Path2 Hydrogen
Germany · Machinery & automation		1.6418322412+0%2026 (no date)Capital increase via authorized capital and new shareholder loans
Techstep
Norway · Software, cloud & internet		2.51871341+263%11 Nov 2026Q3 2026 report: effect of the cost programme (target 218m NOK annualised cost base) and liquidity after the issue
ADLER Group
Germany · Construction & materials		0.7311112636+0%26 Nov 2026Q3 2026 results: portfolio valuation, LTV and progress in sales
Datavault AI
United States · Software, cloud & internet		1.039741220+1,231%2026-11-16 (approx.)Q3 2026 results: test of guidance of approx. 200m USD for 2026 after 10m in H1
Enviro
Sweden · Construction & materials		0.06771222+50%27 Nov 2026Expiry of the requested extension of the restructuring
ESS Tech
United States · Grid & electrical equipment		1.12441221+102%2026-11-12 (approx.)Q3 2026 results: cash, first Bridge orders and any binding Alsym agreement
XCF Global
United States · Oil & gas		2.249211210+143%2026-11-17 (approx.)Q3 2026 results: first quarter with BGN deliveries (over 10m USD in August)
Nordic Mining
Norway · Commodities & uranium		0.87771180+7%3 Nov 2026Q3 2026 report: production, product quality and new capital structure
Casino
France · Food, drinks & restaurants		1.285131166+0%Mar 2027Maturity of the Term Loan B of 1.4 bn EUR
Leclanché
Switzerland · Grid & electrical equipment		0.671,0711162+43%Q4 2026SIX's reaction to the missed final deadline: continued suspension, sanction or delisting
Atlantic Sapphire
Norway · Food, drinks & restaurants		0.536281132+11,800%by about 2026-11-28 at the latestCompulsory redemption of minority shareholders, expected at the offer price of NOK 0.80 (the offer period ended 28/8-2026; a price equal to the offer applies for redemption within 3 months)
Tessellis
Italy · Software, cloud & internet		0.582271101+7%Q4 2026 – Q1 2027End of the 'composizione negoziata' (typically 180 + 180 days from the start in spring 2026): restructuring agreement, composition with creditors or liquidation – determines whether shareholders get anything
Risanamento
Italy · Construction & materials		0.33598177+0%10 Nov 2026The board is to approve the annual accounts for 2025 as well as Q1, H1 and Q3 2026 – the first full figures in over a year, incl. a going concern assessment

Catalyst calendar

Upcoming events the companies or their sources point to. Binary events can move the price sharply either way.

  1. 2026-11-01 (planned)Episurf · Acquisition of five property companies (approx. SEK 505m, binding agreement by 30/9)gradual
  2. 1 Nov 2026Norse Atlantic · The ACMI contract with IndiGo is ending; the last aircraft are returning and must be deployed on own routes (including Europe–Thailand)gradual
  3. 2 Nov 2026SunPower · General meeting (virtual); possible proposals on reverse split and boardgradual
  4. 3 Nov 2026Heron Therapeutics · Q3 report with terms of the Long Grove licence and update on CINVANTI and the strategic processgradual
  5. 3 Nov 2026Nordic Mining · Q3 2026 report: production, product quality and new capital structuregradual
  6. 3 Nov 2026OssDsign · Q3 report: shows whether Catalyst sales turn after the rebuilding of the sales forcegradual
  7. 2026-11-04 (estimated)Accuray · Q1 FY2027 report: order intake (−55% in Q4), China and margin after the cost programmegradual
  8. 4 Nov 2026Cereno Scientific · Q3 report: cash, burn and any financing plangradual
  9. 4 Nov 2026Context Therapeutics · Q3 report: confirmation of first patient in CT-202 and cashgradual
  10. 4 Nov 2026Metacon · Q3 2026 report: cash after loan repayment, milestone payments and order bookgradual
  11. 5 Nov 2026Acarix · Q3 report: sales in the USA, systems and patches, and cashgradual
  12. 5 Nov 2026Ascelia Pharma · Q3 report with cash and burn after the savingsgradual
  13. 5 Nov 2026aTyr Pharma · Q3 report: cash, new CFO and financing plan for phase 3gradual
  14. 5 Nov 2026Medivir · Q3 report (recruitment in FLEX-HCC and start of OI and Perthes studies)gradual
  15. 5 Nov 2026Ocean GeoLoop · Q3 report: cash, burn and status of COOL and the new CEOgradual
  16. 5 Nov 2026Oncopeptides · Q3 report: sales growth, burn and cash (runway)gradual
  17. 5 Nov 2026Smoltek · Q3 report: first quarter with the issue money, cash and any customer agreementsgradual
  18. 6 Nov 2026Brunswick Exploration · Q3 results (estimated date) – cash after the summer programmegradual
  19. 2026-11-06 (stockanalysis estimates 2026-11-09)Ferroamp · Q3 report: does sales hold the Q2 level (60m), and is EBITDA positive per month?binary
  20. 6 Nov 2026Hofseth BioCare · Q3 2026 report: effect of the price increases on ProGo/OmeGo and whether operations are close to EBITDA balancegradual
  21. 6 Nov 2026Lucara Diamond · Q3 2026 report (estimated date): diamond prices, stockpile processing and UGP progressgradual
  22. 9 Nov 2026Mereo BioPharma · Q3 report: cash and status of Sentynl and regulatory dialoguegradual
  23. 9 Nov 2026ShaMaran Petroleum · Q3 2026 results: status of shutdown/restart of Atrush and Sarsang, cash and PSC paymentsgradual
  24. 10 Nov 2026Risanamento · The board is to approve the annual accounts for 2025 as well as Q1, H1 and Q3 2026 – the first full figures in over a year, incl. a going concern assessmentbinary
  25. 11 Nov 2026Capsol Technologies · Q3 2026 report: liquidity, drawdown on the DNB facility and any capital raisebinary
  26. 11 Nov 2026Ensurge Micropower · Q3 2026 report: cash, financing and customer validationbinary
  27. 11 Nov 2026Innoviz · Q3 report: NRE payments, progress towards guidance (67–73m USD) and new programmesgradual
  28. 11 Nov 2026Techstep · Q3 2026 report: effect of the cost programme (target 218m NOK annualised cost base) and liquidity after the issuebinary
  29. 12 Nov 2026Alzinova · Q3 reportgradual
  30. 12 Nov 2026Clavister · Q3 2026 report: do the margin and order intake hold after the record quarter?gradual
  31. 12 Nov 2026Crunchfish · Q3 report: cash, any strategic investor and status of NPCI, GCash and Mercurygradual
  32. 2026-11-12 (approx.)ESS Tech · Q3 2026 results: cash, first Bridge orders and any binding Alsym agreementgradual
  33. 2026-11-12 (approx.)Flux Power · Q1 FY2027 results: revenue, gross margin and liquiditygradual
  34. 12 Nov 2026Greenlane Renewables · Q3 2026 results with order backlog and order intakegradual
  35. 12 Nov 2026Lifecare · Q3 report: cash, burn and update on productiongradual
  36. 12 Nov 2026Questerre Energy · Q3 2026 results: shows whether sales in Brazil have reached the contract minimum, and whether the inventory of 40,000 barrels has been soldgradual
  37. 2026-11-12 (estimated)Rekor Systems · Q3 report: test of the target of positive adjusted EBITDA in H2 2026gradual
  38. 12 Nov 2026Vistagen · Q2 FY2027 report: cash at 30/9, burn and any update on the FDA meetinggradual
  39. 12 Nov 2026VolitionRx · Q3 report: cash after the Lind prepayment and financinggradual
  40. 13 Nov 2026AEON Biopharma · Q3 report with cash and runway after the July issuegradual
  41. 13 Nov 2026Episurf · Q3 report: first quarter with KlaraBo, Livi, Lilium and Setune; NAV per share after dilutiongradual
  42. 13 Nov 2026Excellon Resources · Q3 2026 report (estimated) – first concentrate sales and cash balancegradual
  43. 13 Nov 2026Global Atomic · Q3 results (estimated date) – cash, capex burn and status of DFC conditionsgradual
  44. 13 Nov 2026Gunnison Copper · Q3 2026 results (estimated) – first quarter with commercial production at Johnson Campgradual
  45. 13 Nov 2026HydrogenPro · Q3 report: cash, burn and status of the strategic reviewgradual
  46. 13 Nov 2026IRLAB Therapeutics · Q3 reportgradual
  47. 13 Nov 2026Laramide Resources · Q3 report (estimated date) – cash after the placementgradual
  48. 13 Nov 2026PetroTal · Q3 2026 report (estimated date) – production, cash and possible dividend signalgradual
  49. 2026-11-13 (approx.)Prairie Operating · Q3 2026 results: first quarter under the new minimum production covenant; August production was approx. 27,000 boe/dgradual
  50. 13 Nov 2026Precise Biometrics · Q3 2026 report: first quarter with Fingerprint Cards consolidated, cash after the issue and synergy statusbinary
  51. 13 Nov 2026Touchstone Exploration · Q3 2026 results (estimated) – first quarter with full compressor effect; status of covenant waiver and going concernbinary
  52. 13 Nov 2026Volatus Aerospace · Q3 2026 results (estimated date) – shows whether the postponed defence order of approx. 2.6m C$ has been deliveredgradual
  53. Nov 2026KALA BIO · Due diligence on the telehealth acquisition is completedbinary
  54. Nov 2026Metacon · CFO Mattias Jansson is stepping downgradual
  55. Nov 2026OHLA · Q3 2026 report: whether the margin improvement in construction (7.3% EBITDA margin) holds, and whether the cash flow continuesgradual
  56. 2026-11 (estimated)Patagonia Gold · Q3 2026 report – first full quarter of ramp-up at Calcatreu (production, sales, debt)gradual
  57. Nov 2026PyroGenesis · Q3 2026 results (Q3 2025 came in November) – shows whether revenue growth and the lower loss hold, and how liquidity is after the July maturitygradual
  58. Nov 2026Sernova · Shareholder meeting and closing of the merger of Seraxis into BetaNova Biotherapeutics (requires 2/3 majority, court and TSX approval); Sernova shareholders get about 50%binary
  59. Nov–Dec 2026Vantiva · Move of the listing to Euronext Growth (at the earliest two months after 23/9-2026, requires Euronext's approval)gradual
  60. 2026-11-16 (approx.)Datavault AI · Q3 2026 results: test of guidance of approx. 200m USD for 2026 after 10m in H1binary
  61. 2026-11-17 (approx.)Canaan · Q3 2026 results: guidance is only 11–15m USD in revenue; focus on cash and burngradual
  62. 2026-11-17 (approx.)XCF Global · Q3 2026 results: first quarter with BGN deliveries (over 10m USD in August)gradual
  63. 18 Nov 2026Bluelake Mineral · Q3 report (estimated date): cash after the issue, drilling results at Joma/Gjersvik and timeline for the PFSgradual
  64. 18 Nov 2026KALA BIO · Q3 reportgradual
  65. 19 Nov 2026BioPorto · Q3 report: NGAL growth after recall and cash balancegradual
  66. 19 Nov 2026Elliptic Labs · Q3 2026 report: does revenue show that the laptop contracts exceed the minimum thresholds?binary
  67. 2026-11-19 (approx.)Evogene · Q3 2026 results: cash burn and any paid ChemPass agreementsgradual
  68. 19 Nov 2026Scandinavian Medical Solutions · Annual report 2025/26: actual EBITDA vs −9 to −13m, inventory value, writedowns and expectations for 2026/27gradual
  69. 20 Nov 2026Desert Control · Q3 2026 report: first evidence of whether guidance of about USD 2m for 2026 holdsbinary
  70. 20 Nov 2026Initiator Pharma · Q3 report with status of recruitment for the vulvodynia study and cashgradual
  71. 20 Nov 2026Premier American Uranium · Q3 report (estimated date) – cash after the drilling seasongradual
  72. approx. 2026-11-24Danish Aerospace · Q3 update: liquidity, whether the postponed orders have come in, and whether guidance (18–20m DKK) holdsbinary
  73. 24 Nov 2026SBB · Q3 2026 report: LTV, refinancing of the 13% preferred shares and plan for 2027 maturitiesgradual
  74. 24 Nov 2026Silver Storm Mining · Report for the quarter to 30/9/2026 (estimated) – first sales from the oxide and sulphide circuit and new cash balancegradual
  75. 25 Nov 2026Cantargia · Q3 report: cash after the share issue and update on the MDS/AML studygradual
  76. 25 Nov 2026Lahontan Gold · Q3 report (estimated date) – cash and burngradual
  77. 25 Nov 2026Norse Atlantic · Q3 2026 report (summer quarter): cash, fuel costs and status of the strategic reviewgradual
  78. 25 Nov 2026Nykode · Q3 report: update on recruitment in Abili-T and booking of the lost tax casegradual
  79. 26 Nov 2026ADLER Group · Q3 2026 results: portfolio valuation, LTV and progress in salesgradual
  80. 26 Nov 2026K33 · Q3 2026 report: liquidity, bitcoin holdings and whether the MiCA expansion gives volumebinary
  81. 26 Nov 2026Spanish Mountain Gold · Q3 report (estimated date) – cash and burngradual
  82. 2026-11-27 (estimated)Defense Metals · Q2 FY2027 results (to 30/9) – cash and status of the DFSgradual
  83. 27 Nov 2026Elicera Therapeutics · Q3 report and updated follow-up on durability of responders in phase 1gradual
  84. 27 Nov 2026Enviro · Expiry of the requested extension of the restructuringbinary
  85. 27 Nov 2026Guanajuato Silver · Q3 2026 report (estimated date) – margin, cash and AISC after record capexgradual
  86. 2026-11-27 (estimated)HPQ Silicon · Q3 2026 results – shows whether new capital has been raised, and how the HSPI transaction is bookedgradual
  87. 27 Nov 2026Purepoint Uranium · Q3 report (estimated date) – cash and financing needgradual
  88. Q4 2026–Q1 2027 (no date)Acarix · New capital raise needed, as cash lasts about 7 monthsbinary
  89. Q4 2026AEON Biopharma · IND submission for the CMAP pharmacodynamics study in healthy volunteersgradual
  90. Q4 2026Akobo Minerals · Vertical shaft reaches first lateral level – target of 50 kg/month (about 5x current)gradual
  91. by about 2026-11-28 at the latestAtlantic Sapphire · Compulsory redemption of minority shareholders, expected at the offer price of NOK 0.80 (the offer period ended 28/8-2026; a price equal to the offer applies for redemption within 3 months)binary
  92. after compulsory redemption (Q4 2026)Atlantic Sapphire · Delisting from Oslo Børsbinary
  93. Q4 2026aTyr Pharma · Start of study activities for the new phase 3 study in pulmonary sarcoidosis (FVC endpoint)gradual
  94. Q4 2026BioPorto · Target of 60 US hospitals in the RUO programme by end-2026 (54 at end of Q2)gradual
  95. Q4 2026Brunswick Exploration · Assays from the summer drilling at Mirage (about 4,000 m along MR-1 and MR-4), announced 'in the coming weeks'gradual
  96. Q4 2026Brunswick Exploration · Assays for the 202 m wide spodumene intercept in the Anais dyke at Anatacau Main (today only a visual estimate)binary
  97. Q4 2026CanAlaska · Assay results from the 2026 summer drilling at West McArthur (step-outs along the C10S corridor from Pike Zone; the programme ended in September)binary
  98. Q4 2026Cassiar Gold · Assay results from the 2026 drilling campaign (7,400 of 10,000 m drilled at Taurus and Newcoast as of 17/9)gradual
  99. Q3–Q4 2026 (no fixed date)Crunchfish · Board decision on CBDC in the Caribbean (expected in Q3) and first commercial agreement with revenue, which the CEO expects 'this year'binary
  100. Q4 2026–Q1 2027Crunchfish · Financing needed: strategic investor or new issue, as cash lasts until about March 2027binary
  101. Q4 2026 – H1 2027Deoleo · The Spanish government's approval or blocking of a foreign takeover (investment screening)binary
  102. Q3–Q4 2026Desert Control · Conversion of 42 pilot trials in California (agriculture and golf) into commercial contractsgradual
  103. Q4 2026Dicot Pharma · Decision on the EU application (CTA) for phase 2bbinary
  104. Q4 2026District Metals · New Swedish government after the election 13/9-2026 - its line on uranium mining, alum shale and the removed municipal vetobinary
  105. Q4 2026 (early)Ebusco · Extraordinary general meeting: change of auditor from EY to CFA and Rhein Holding's seat on the supervisory boardgradual
  106. Q4 2026Elicera Therapeutics · Start and first patients in phase 2a of CARMA (ELC-301) after the Swedish Medical Products Agency's approval in September 2026gradual
  107. Q4 2026Emerita Resources · Publication of the PFS for Iberian Belt West (NPV, IRR, capex) - 'in the coming weeks' after extended reviewbinary
  108. Q4 2026Ensurge Micropower · Possible signing of a multi-phase development agreement with a large external customer ('in the final stage' at 31/7/2026)binary
  109. Q4 2026F3 Uranium · 1:10 consolidation of the shares once TSXV accepts it (631.8m to approx. 63.2m shares)gradual
  110. Q4 2026F3 Uranium · Remaining results from the 2026 summer programme (about 4,000 m; the A4 conductor, Broach Lake, JR's south-eastern extension and the Tetra area)binary
  111. Q4 2026Flux Power · Waiver/amendment of the Gibraltar credit line and requirement of USD 4m in new equitybinary
  112. Q4 2026GenSight Biologics · Meeting with the FDA on the final RECOVER protocol; last patient in the dose study REVISE (December)binary
  113. Q4 2026Gunnison Copper · Preliminary column leach results from the Gunnison project (recovery and acid consumption)binary
  114. Q4 2026KALA BIO · Nasdaq Hearings Panel decides whether the share can remain listed (no cure period)binary
  115. Q4 2026Lahontan Gold · Completion of the Emergent Metals acquisition (court-approved plan of arrangement) and drilling results from West Santa Fe (rig mobilized 21/9-2026)gradual
  116. Q4 2026Leclanché · SIX's reaction to the missed final deadline: continued suspension, sanction or delistingbinary
  117. Q4 2026Lucara Diamond · Open pit mine ending; transition to processing stockpiled oregradual
  118. Q4 2026 – Q1 2027Minesto · Capital raise necessary (amount and form unknown)binary
  119. Q4 2026Nordic Mining · Resolution of the dispute over Barton's termination of the garnet offtake agreementbinary
  120. Q4 2026Nykode · Possible repair issue at NOK 4.40 for shareholders who did not receive an allocationgradual
  121. Q4 2026Observe Medical · Target of positive operating cash flow; if not reached, new financing is required (going concern qualification)binary
  122. Q4 2026 (ongoing)Oroco Resource · Remaining phase 2 analyses from South Zone and start of drilling in Pillar Zonegradual
  123. Q4 2026PetroTal · Results from well 25H, the first of eight new wells at Bretaña (drilled from 21/9/2026)binary
  124. Q4 2026Photon Energy · New vote among the bondholders on a joint representative and an independent business review, then a concrete restructuring proposalbinary
  125. Q4 2026Premier American Uranium · More drilling results from Kaycee (Rustler/Outpost) in cycles of about 6 weeks; 50 of the planned holes had been drilled by mid-Augustgradual
  126. Q4 2026Purepoint Uranium · Assay results from the 2026 summer programme at Nova (hole NV26-11: 5.6 m continuous radioactivity, peak 53,300 cps; laboratory results awaited)binary
  127. Q4 2026Salmon Evolution · First harvest from phase 2 (Indre Harøy) and handover of the last 8 of 12 growth tanks during 2026gradual
  128. Q4 2026 (report approx. Feb. 2027)Senzime · The company's target of profitability in Q4 2026binary
  129. Q4 2026Silver Storm Mining · Transition from stockpile to underground ore (Quebradillas and Rosarios) and stable operation of the sulphide circuit at 1,250 t/dgradual
  130. Q4 2026Southern Silver · Updated resource estimate with Puro Corazon (planned for Q3 2026)gradual
  131. Q4 2026Spanish Mountain Gold · Completion of the 60,000 m drilling program for the feasibility study (31,587 m done) and a draft detailed project description for the environmental assessmentgradual
  132. Q4 2026 (ongoing)Sun Summit Minerals · Assay results from 55 holes (over 16,000 m) on the Creek, Finn and Schmitt zonesbinary
  133. Early in Q4 2026Sun Summit Minerals · Metallurgical report for the JD projectgradual
  134. Q4 2026–2027Techstep · Strategic review after the issue, which may lead to delisting or structural changesbinary
  135. Q4 2026 – Q1 2027Tessellis · End of the 'composizione negoziata' (typically 180 + 180 days from the start in spring 2026): restructuring agreement, composition with creditors or liquidation – determines whether shareholders get anythingbinary
  136. Q4 2026Tobii · Outcome of strategic review: divestment/partnership in Autosense or capital raisebinary
  137. Q4 2026Touchstone Exploration · Results from the two-well oil campaign at WD-4 (first well started mid-September 2026; second well paid for by the drilling contractor)gradual
  138. Q4 2026 (no fixed date)Tullow Oil · Agreement with Ghana's government on paying the tax bill of up to USD 393m – determines liquiditybinary
  139. Q4 2026Viaplay · Completion of the sale of Holland (142 m EUR) – net debt falls about 30%gradual
  140. Q4 2026Volatus Aerospace · Delivery of the first 100 tactical ISR drones to the Canadian Armed Forces; then options for up to 4,900 more systems (framework max. C$25m over 5 years)gradual
  141. 30 Nov 2026aTyr Pharma · Nasdaq deadline to reach USD 1 – reverse split or delistingbinary
  142. 30 Nov 2026Hilbert Group · Q3 report: fee income, effect of the savings, cash and use of the LDA facilitybinary
  143. 7 Dec 2026XCF Global · Nasdaq's deadline to regain USD 1 – reverse split or delistingbinary
  144. 9 Dec 2026Scandinavian Medical Solutions · General meeting (possible authorization for capital increase)gradual
  145. 14 Dec 2026Risanamento · General meeting (2nd call 15/12) – possible capital increase or measures under art. 2446/2447binary
  146. Dec 2026–Mar 2027Beowulf Mining · ISP decision on the Bacchus investment (review started 10/9, up to 3–6 months)binary
  147. latest about December 2026Nel · New CEO (Volldal stepped down with six months' notice in June)gradual
  148. 15 Dec 2026Rekor Systems · Maturity of the 15 m USD Series A Prime Revenue Sharing Notes (13.25%) – refinancing or issuebinary
  149. Dec 2026VolitionRx · Monthly repayments on the Lind loan from 2026 begin (probably in shares)gradual
  150. Dec 2026Zenith Energy · Half-year report at 30/9-2026 (latest end of December) with status on cash, bond maturity and the Daybreak acquisitiongradual
  151. 17 Dec 2026CanAlaska · Quarterly report (estimated date) - cash after the summer programgradual
  152. 18 Dec 2026DMG Blockchain · Annual accounts 2025/26 (Q4) with bitcoin holdings and debtgradual
  153. 18 Dec 2026Emerita Resources · Annual accounts for financial year 2026 (estimated date) – cash and financinggradual
  154. 18 Dec 2026Mega Uranium · Annual accounts for the financial year to 30/9-2026 (estimated date) – updated portfolio and debtgradual
  155. 22 Dec 2026Heron Therapeutics · Nasdaq deadline to reach USD 1; otherwise application for 180 more days in exchange for a reverse splitbinary
  156. 2026-12-23 (estimated)Focus Graphite · Annual accounts FY2026 (to 30/9) – cash, going concern and warrant statusgradual
  157. 29 Dec 2026Prairie Operating · Nasdaq's deadline to regain USD 1 (extension or reverse split)binary
  158. 2026–2027 (ongoing)ADLER Group · Further sales of projects and properties to repay 1L New Money debt (EUR 201m so far in 2026)gradual
  159. 2026 (no date)Alligator Bioscience · Sale or licence of mitazalimab, which the company will try in 2026binary
  160. Turn of the year 2026/27Alzinova · First patient in the global phase 2 of ALZ-101 (about 120 patients)gradual
  161. 31 Dec 2026Beowulf Mining · Extended deadline in the settlement agreement with Alumni Capitalbinary
  162. 2026–2027Capsol Technologies · Conversion of MoU with a US utility (CapsolGT for gas power) and about 150 gas turbine leads into paid projectsbinary
  163. 2026–2028Clavister · Delivery of the SEK 642m order book (defense) and new call optionsgradual
  164. 2026–2027Danish Aerospace · Orders for E4D training equipment and medical equipment for commercial space stations that are to replace the ISSbinary
  165. 2026–2027Danish Aerospace · Development of the ESA motion capture system (space and defence) and possible first defence orders after the name changegradual
  166. Oct. 2026Defense Metals · Closing of the placement of up to C$6m at C$0.14 with a lead order from the chairmangradual
  167. 2026–2027District Metals · Drilling programme of 5,000–7,000 m at Viken and the alum shale properties (depends on drilling permits) to convert inferred to indicatedgradual
  168. Not set (after Sep. 2026)Emerita Resources · TSJA's ruling in the administrative case on the Aznalcóllar tender; the suspension was lifted in September 2026binary
  169. no date (autumn 2026)Evogene · Special takeover offer from Pure Capital/Invest Pro and clarification of the contested general meeting – may change board and strategybinary
  170. End of 2026Excellon Resources · 400 ramp completed and updated mine plan with a timetable for 600 t/dgradual
  171. Winter 2026/27F3 Uranium · First drilling season under new CEO Ross McElroy (former CEO of Fission Uranium, which was sold to Paladin for 1.14 bn C$)gradual
  172. Ongoing 2026-2027Ferrexpo · Resumption of VAT refunds (102 m USD receivable) and return of more pellet lines; a ceasefire in Ukraine would be the big gradual drivergradual
  173. H2 2026Ferroamp · The company's target of positive EBITDA per monthbinary
  174. 2026–2027Ferroamp · Rollout via Aira in Germany, Italy and the UK and via Vattenfall and Elvy in Swedengradual
  175. Oct. 2026Focus Graphite · Canada Investment Summit with Prime Minister Carney, where Lac Knife is included in the 'Investment Deal Book' – possible contact with strategic investorsgradual
  176. End of 2026Greenlane Renewables · Cascade LF production-ready via Panasonic in São José dos Campos, Brazil (landfill gas)binary
  177. End of 2026Gunnison Copper · Johnson Camp at nameplate (25m lbs/year) and approval of the Mined Land Reclamation Plangradual
  178. No date (2026–2027)Hexagon Purus · 'Structural measures' for the convertible bonds – decide how much of the company shareholders keepbinary
  179. Undated (applied July 2026)Hilbert Group · Decision on MiCA and payment license in Maltabinary
  180. late 2026Hofseth BioCare · Planned FDA IND application for FT-002a-O (AecorBio)gradual
  181. No date given (negotiations resumed Sept. 2026)HPQ Silicon · Possible binding agreement on a 1,000 t/year fumed silica plant or with a global fumed silica producerbinary
  182. monthly from 2026Hyperscale Data · Monthly status reports on the Michigan AI data centre and start-up of the first 20 MW under the master services agreementgradual
  183. end of 2026Initiator Pharma · Topline data from phase 2a with pudafensine in vulvodynia (24 women, placebo-controlled crossover)binary
  184. 2026 (rest of the year)Innoviz · Target of 2–3 new programme wins (automotive, robotaxi via Mobileye, Perciz defence)binary
  185. 2026 (company target, no exact date)IRLAB Therapeutics · Partner or licence agreement funding phase 3 for mesdopetam (Parkinson's dyskinesia)binary
  186. 2026–2027K33 · European expansion after MiCA license (passport to SE, DK, FI and DE) and new institutional partners such as Coinmotiongradual
  187. Not set ('soon to be completed' as of Aug. 2026)Lahontan Gold · Updated PEA for Santa Fe with the new resource of 2.39 Moz AuEq and phase 2 sulphide processingbinary
  188. autumn 2026Lifecare · 'Controlled manufacturing' established at Ocean TuniCell's premises in Bergengradual
  189. 31 Dec 2026Lion One Metals · Deadline for repayment/refinancing of the Nebari loan (about 31.2 m US$) under the forbearance agreementbinary
  190. 2026–2028Mega Uranium · Construction of NexGen's Rook I (licence granted 5/3-2026, valid to 2036) – progress and financing drive the main assetgradual
  191. End of 2026Mereo BioPharma · Update from FDA/MHRA on a possible path for setrusumab in children with osteogenesis imperfecta (FDA open to alternative fracture analysis)binary
  192. 2026 (ongoing)Midsummer · Delivery and revenue recognition of most of the SEK 236m ordergradual
  193. Ongoing 2026-27MindMaze Therapeutics · The reimbursement studies SwissNeuroRehab (Switzerland) and REACT-AVC (France) and rollout via Vibra Healthcare in the USAgradual
  194. 2026–2027Minesto · The EIB-backed investment case for the first tidal farm (Dragon Farm) in the Faroe Islands – a funded farm would be the first commercial breakthroughbinary
  195. The 2026–27 season (southern summer)Mogotes Metals · Up to 20,000 m of drilling at Filo Sur: expansion of Albor and Cruz del Sur and first porphyry tests at Luz del Sol-Cuenca and Mesetabinary
  196. autumn 2026Nel · The EU's delegated acts on qualifying hydrogen (postponed from July)binary
  197. before the end of 2026Norse Atlantic · Completion of the strategic review with J.P. Morgan (sale, merger or partnership); several parties have signed confidentiality agreementsbinary
  198. 2026–2027Oncopeptides · Launch in Central and Eastern Europe via Salus (11 countries; list price in Slovenia has been set)gradual
  199. 2026 (no date)Path2 Hydrogen · Capital increase via authorized capital and new shareholder loansbinary
  200. 2026–27Pharol · First investments or new strategy under chairman João Moreira Rato (approved by the ECB on 17/8-2026, mandate to 2028)gradual
  201. Turn of the year 2026/27PILA PHARMA · Result of part 1: safety and tolerability at high doses plus the first weight databinary
  202. no date (autumn 2026)Prairie Operating · Borrowing base redetermination on the credit facility (USD 475m, 436m drawn) and refinancing of the remaining Series Fbinary
  203. 2026–2027Precise Biometrics · Realisation of at least 45m SEK of annual cost synergies (primarily in 2026)gradual
  204. autumn 2026Realbotix · Launch of new robot line: tabletop model at about USD 12,000 and full size at about USD 55,000gradual
  205. End of 2026Sintana Energy · High-impact exploration well on PEL 90 (Namibia), Sintana fully fundedbinary
  206. Undated (announced August 2026)Smoltek · 3,000-hour durability test of electrolysis electrodes with Heraeusbinary
  207. Ongoing 2026Southern Silver · Drill results from Cerro Las Minitas and Puro Corazon (latest 35.0 m at 399 g/t AgEq 21/9-2026)gradual
  208. No date (decree sent to the Conseil d'État 2/7-2026)Stenocare · French decree on price and reimbursement for medical cannabis is adopted, so ASTRUM 10-10 can apply for accessbinary
  209. October 2026Touchstone Exploration · Workover of Cascadura-3ST1 and recompletion of Cascadura-5 (after a successful solvent squeeze on Cascadura-2ST1)gradual
  210. 2026-2027OHLA · Refinancing of the 9.5–9.75% bonds at a lower rate (planned new bond) – will lift net income markedlygradual
  211. 2026-2027Silver Storm Mining · Drill results from surface and underground drilling at La Parrilla financed by the Sprott issuegradual
  212. 4–18 Jan 2027Alzinova · Exercise of TO5 at SEK 0.50 (up to SEK 81m)binary
  213. 8–22 Jan 2027Alligator Bioscience · Exercise of TO15 (up to 1.47bn shares, max. SEK 29.4m)binary
  214. 11 Jan 2027Canaan · Nasdaq's deadline to regain USD 1; requires a reverse split, otherwise delistingbinary
  215. Jan–Feb 2027Maisons du Monde · Revenue for 2026 (incl. Christmas trade) - shows whether the decline stops under the new ownersgradual
  216. Jan 2027Questerre Energy · Hearing on objections in the constitutional case against Quebec's revocation of the licences (the attorney general's reply was set for September 2026)gradual
  217. 18 Jan – 15 Feb 2027Smoltek · Pricing and exercise of TO 9 (48–68m SEK, only if the price is above approx. 2.19 kr) and deadline for conversion of the convertible loan 31/1binary
  218. 19 Jan 2027SunPower · Nasdaq deadline to reach USD 1; otherwise application for 180 more days in exchange for a reverse splitbinary
  219. 2027-01-20 (approx.)Flux Power · Nasdaq's deadline to regain USD 1binary
  220. 25 Jan 2027Context Therapeutics · Nasdaq deadline to reach USD 1 (possible 180-day extension)binary
  221. 27 Jan 2027Cassiar Gold · Annual accounts for financial year 2026 (estimated date) – cash and spendinggradual
  222. 1 Feb 2027Vistagen · Nasdaq deadline to reach USD 1; reverse split or delistingbinary
  223. 2027-02 (H2 report, expected approx. 27/2 as in 2026)Observe Medical · Full-year 2026 figures: sales, cash and new covenant with Innovation Norwaygradual
  224. 2027-02 (Q4 report)OssDsign · Full-year 2026 figures and any targets for 2027 under the new managementgradual
  225. 16 Feb 2027KebNi · Annual accounts 2026: first year after the issue and the doubling of IMU capacitygradual
  226. 16 Feb 2027Mereo BioPharma · Nasdaq deadline to reach USD 1 (change of ADS ratio expected)binary
  227. 22 Feb 2027Datavault AI · Nasdaq's deadline to regain USD 1 – reverse split or delistingbinary
  228. Q1 2027AEON Biopharma · Start of the CMAP study (milestone that may trigger milestone warrants)gradual
  229. Q1 2027aTyr Pharma · Topline data from the phase 2 study EFZO-CONNECT in SSc-ILD (lung disease in systemic sclerosis)binary
  230. Q1 2027Cantargia · Start of phase 1b study with nadunolimab + daraxonrasib (RAS inhibitor) in pancreatic cancer at US clinics; first data 9–12 months latergradual
  231. Q1 2027Context Therapeutics · Start of phase 1b dose expansion with CTIM-76 in platinum-resistant ovarian cancergradual
  232. Q1 2027Desert Control · Full-year 2026 figures vs guidance and the new burn level after the share issuegradual
  233. End of 2026 / Q1 2027Excellon Resources · Updated resource estimate for Mallay with deeper drilling (below the 4090 level)gradual
  234. Q1 2027GenSight Biologics · Structural financing must be in place before March 2027; new GMP batch released in March 2027binary
  235. Q1 2027IRLAB Therapeutics · CEO Kristina Torfgård steps down; new CEOgradual
  236. Late 2026 or Q1 2027KALA BIO · Definitive agreement and closing of the telehealth acquisition (about USD 15m, cash and shares)binary
  237. Q1 2027 (March)Latecoere · Annual accounts 2026: shows whether the aerostructure loss has turned and whether FCF holdsgradual
  238. Q1 2027Sernova · First patients dosed in the FDA-approved phase 1/2 with SR-02 (stem cell-based islet cells, NCT07581197) and planned Nasdaq listing of BetaNovagradual
  239. Q1 2027Spanish Mountain Gold · Formal submission of the detailed project description in the resumed BC/federal environmental assessmentgradual
  240. Q1 2027Sun Summit Minerals · First NI 43-101 resource estimate for JDbinary
  241. Q1 2027Zenith Energy · The ICSID tribunal's award in the case against Tunisia (claim about US$572.65m) after the hearing in Paris in April 2026 and final written submissions in September 2026binary
  242. Mar 2027Casino · Maturity of the Term Loan B of 1.4 bn EURbinary
  243. By 2027-03-22 at the latestInnoviz · Reverse split (approved 1:5–1:20) to reach USD 1 before the Nasdaq deadlinebinary
  244. 29 Mar 2027Evogene · Nasdaq's extended deadline to regain USD 1 (reverse split 1:2–1:15 approved)binary
  245. H1 2027Lifecare · New funding required (runway into Q2 2027)binary
  246. H1 2027Nykode · Selection of first lead programme on the tolerance platformgradual
  247. H1 2027PILA PHARMA · Financing of part 2 (38 participants), probably an issuebinary
  248. H1 2027Premier American Uranium · Updated PEA for Cebolleta after Hazen's 42-week metallurgy programme; 90% recovery instead of 80% could lift NPV from approx. $84m to approx. $160mbinary
  249. May 2027Dicot Pharma · Exercise of TO 7 warrants (about 365m)gradual
  250. May 2027Norse Atlantic · Maturity of the secured facility of 52 m USD (15% interest)binary
  251. Q2 2027Context Therapeutics · First safety and efficacy data for CTIM-76 given every third weekbinary
  252. around Q2 2027Medivir · FLEX-HCC fully enrolled (plan: all patients within 12 months from May 2026)gradual
  253. by 2027-06-13 at the latestPremier American Uranium · Closing of the Colorado sale to DISA (DOE review) and release of US$5m from escrowbinary
  254. Jun 2027Tessellis · Canarbino's lease agreement for B2C expires (12 months from 1/6-2026, possibly +3 months); final purchase at EV EUR 27m plus earn-outbinary
  255. after 2027-07-30Maisons du Monde · The consortium's commitment not to seek delisting expires - possible buyout of the last 4.8% (price unknown)binary
  256. 6 Aug 2027VolitionRx · Deadline to regain NYSE American compliance (equity)binary
  257. 19 Aug 2027Ebusco · Maturity of the extended Heights loanbinary
  258. by 2027-08-21 at the latestK33 · Exercise window for Sixty Six Capital's call option on 100–200 BTC at USD 100,000; the bitcoin price drives K33's look-through exposurebinary
  259. 31 Aug 2027Ensurge Micropower · Mandatory conversion of convertible loans of NOK 80m plus PIK interestgradual
  260. By 2027-09-30 at the latestQuesterre Energy · Milestone for PX Energy: FCF of US$30m, which triggers contingent consideration shares and shows whether the acquisition holds upgradual
  261. 30 Sep 2027Tullow Oil · Deadline for a binding sales agreement for the assets; otherwise the maturity of the 2028 bonds is brought forward to 15/5-2028binary
  262. 1–15 Oct 2027Bluelake Mineral · Exercise of TO7:1 at SEK 1.70: gives up to approx. SEK 70m if the share price is above strike, and otherwise a new funding gapbinary
  263. H2 2027GenSight Biologics · Planned start of the phase III RECOVER study (subject to funding)gradual
  264. H2 2027Lucara Diamond · The first underground development ore replaces stockpiled orebinary
  265. By about 2027-11 at the latestMogotes Metals · Expiry of Rio Tinto's 15-month exclusivity on Filo Sur (can be extended 6 months) – possible project agreement, acquisition or step-up to 9.99%binary
  266. Nov 2027Photon Energy · Maturity of the green bond 2021/2027 (78.8 m EUR)binary
  267. 30 Nov 2027Cereno Scientific · Maturity of the SEK 175m convertible (conversion at SEK 10 or repayment)binary
  268. 2027AEON Biopharma · Back to the FDA with a combined evidence package before BLA (351(k))binary
  269. 2027BioPorto · Recruitment and results in the adult validation study for ProNephro AKI (about 900 patients) and new financinggradual
  270. Winter 2027CanAlaska · First drilling season under new exploration director James Sykes (project leader at NexGen's Arrow discovery in 2014), appointed 21/9-2026gradual
  271. 2027Cantargia · Phase 2a data for nadunolimab + azacitidine/venetoclax in high-risk MDS/AML (about 40 patients; 5/5 complete remission in phase 1b)binary
  272. 2H 2027Context Therapeutics · First phase 1a data for CT-202 (Nectin-4 x CD3) in bladder, bowel and triple-negative breast cancerbinary
  273. 2027DMG Blockchain · Energization of the first phase of the AI data center at Christina Lake (postponed from 31/12-2026)binary
  274. Undated (expected before energisation in 2027)DMG Blockchain · Definitive 12-year agreement for 50 MW of AI colocation with an anonymous tenant with an investment-grade guaranteebinary
  275. 2027Elicera Therapeutics · Start of phase 1/1b with ELC-401 (iTANK-CAR-T against glioblastoma)gradual
  276. 2027Elliptic Labs · First revenue from wearables/smart glasses and the Edge AI platform (commercial discussions under way)gradual
  277. 2027Hyperscale Data · Planned spin-off of ACG (Ault Capital Group) to shareholdersbinary
  278. 2027Intrum · Refinancing of new money notes (maturing Dec. 2027) and first exchange notes – test of market access after Chapter 11binary
  279. Mid-2027IRLAB Therapeutics · First results from LIFT-PD (phase 1b, linepemat/IRL757 for apathy in Parkinson's, Otsuka-funded)binary
  280. 2027Lahontan Gold · Mine Plan of Operation (BLM) and state permits; construction start targeted for 2027binary
  281. Early 2027Mereo BioPharma · Possible start of global phase 3 for alvelestat and Sentynl's decision to exercise the option (USD 40m)binary
  282. 2027Nykode · First interim analysis in the randomised phase 2 Abili-T (abi-suva, HPV16+ head and neck cancer) at about 1/3 of patientsbinary
  283. 2027Nykode · Reopening at the Tax Appeals Board or a lawsuit over NOK 325mbinary
  284. 2027Oncopeptides · Target of positive cash flow during the year – or new financing if it slipsgradual
  285. 31 Dec 2027Patagonia Gold · Maturity of the Cantomi loan (about US$50 m incl. interest) – extension, conversion or refinancingbinary
  286. Mid-2027PetroTal · Target of restoring production to approx. 20,000 barrels/day after the 8-well programme; reinstating the dividend depends on itgradual
  287. summer 2027 (analyst estimate)PILA PHARMA · Result of part 2 of PP-CT04 with weight change after 12 weeks vs placebobinary
  288. Winter 2027Purepoint Uranium · JV budget and winter drilling at Dorado with IsoEnergy as well as partner-funded programs with Cameco and Oranogradual
  289. Mid-2027Salmon Evolution · Targeted run-rate of 14,600 tons HOG per year (vs guidance of approx. 6,000 t in 2026)gradual
  290. 2027SBB · Senior bonds of SEK 6.0bn fall due (21.3bn in 2027–2029); decides whether SBB can refinance in the market or must sell/dilutebinary
  291. Mid-2027Sernova · First data from the SR-02 trialbinary
  292. 2027Sintana Energy · Chevron's high-impact well on PEL 82 (fully carried)binary
  293. H1 2027Southern Silver · Updated PEA for the combined Cerro Las Minitas project – with higher metal prices NPV could rise markedly from US$501mbinary
  294. 2027Tobii · Target of sustained positive operating cash flow from 2027, carried by Autosensegradual
  295. 2027Tullow Oil · First hearing in the second ICC tax case (interest expenses, 190.5 m USD)binary
  296. 2027 (no fixed date)Vantiva · General meeting on possible convertible bondbinary
  297. Approx. March 2027Verimatrix · Annual accounts 2026: does it reach the Anti-Piracy EBITDA target of at least USD 3m, and does revenue return to growth?gradual
  298. FY2027Xtract One · Installation of C$27.2m in agreements awaiting installation – must be converted into revenue and subscriptionsgradual
  299. Q1 2028Hexagon Purus · Maturity of the first convertible loanbinary
  300. Q1 2028Salmon Evolution · Repayments on the bank facility (DNB/Nordea) begingradual
  301. By 2028-03-31 at the latestFocus Graphite · Completion of the NRCan-backed demonstration plant for thermal purification (ultra-pure graphite for batteries and defense)gradual
  302. H1 2028Gunnison Copper · PFS for the Gunnison project and changed key permitsgradual
  303. H1 2028Lucara Diamond · Full underground production at Karowegradual
  304. H1 2028Spanish Mountain Gold · Feasibility study and construction decision (company target)binary
  305. Jun 2028Kongsberg Automotive · EUR 110m bond matures - possible early refinancing at a lower rate; target of 6.5% EBIT margingradual
  306. Jun 2028Viaplay · Maturity of 6.9 bn SEK in loans and MTNbinary
  307. 1–15 Jul 2028Bluelake Mineral · Exercise of TO7:2 at SEK 1.87gradual
  308. Q4 2028Cereno Scientific · Topline from phase 2b EPIMODE with CS1 in PAHbinary
  309. Dec 2028ADLER Group · First large bond maturity (after the extensions to Dec 2028, Dec 2029 and Jan 2030)binary
  310. Mid-2028BioPorto · Expected FDA approval of ProNephro AKI for adultsbinary
  311. H2 2028Global Atomic · Commissioning of the process plant and first yellowcake from Dasabinary
  312. 2028Intrum · Target of servicing gearing of 3.0x and up to SEK 7bn of extra portfolio investments 2026–2028gradual
  313. No dateAccuray · Samsung collaboration on volumetric imaging for CyberKnife (non-binding LOI)gradual
  314. no date from HenliusAlligator Bioscience · Data from Henlius' global phase 3 with HLX22 in first-line HER2+ gastric cancer (milestones to AbClon, of which Alligator gets 35%)binary
  315. no date from the companyAlzinova · Fujirebio is assessing a broader collaboration on a blood-based Alzheimer's test after the completed Amsterdam UMC studybinary
  316. no date from the companyAscelia Pharma · Partnership agreement on Orviglance and financing needed within about 2 quartersbinary
  317. No dateCantargia · Possible milestone payments from Otsuka for CAN10 (up to USD 580m in total)binary
  318. OngoingCanaan · The bitcoin price: drives machine sales, own mining (243 BTC in Q2) and the value of the 1,915 BTC holdinggradual
  319. no date (awaiting regulatory approval)Datavault AI · Closing of the BankWyse acquisition (digital asset custody) and integration of NYIAXgradual
  320. No date givenDefense Metals · NRCan decision on up to C$32m for the feasibility program for the concentrator and hydrometallurgybinary
  321. Not disclosed (the company only reports on the final outcome)Diamyd Medical · Outcome of strategic review: sale/out-licensing of retogatein, sale of the Umeå factory or a transaction with one of the shortlisted counterpartiesbinary
  322. No dateEbusco · LC facility of about EUR 30m with Asian partner and Gotion guaranteebinary
  323. No dateEbusco · Strategic transaction: sale of a controlling stake in the bus division or JVbinary
  324. no date from the companyElicera Therapeutics · Possible non-exclusive licence agreement for iTANK with a CAR-T companybinary
  325. No dateEnviro · The arbitration case with Infiniteria over the joint venture terminations and the licence rightsbinary
  326. Unresolved (appeal pending)Ferrexpo · Bankruptcy petition against the operating company FPM and the state's claim to 49.5% of FPM via ARMA - decides whether shareholders keep the assetbinary
  327. No date givenGlobal Atomic · Fulfilment of DFC's five conditions (export route, extended mine convention, repatriation guarantee, agreement with the state, final loan documentation) and possible sale of a minority stake to the JV partnerbinary
  328. OngoingGreenlane Renewables · New orders for Cascade H2S desulfurization and upgrading plants (latest C$2.5m 19/8-2026)gradual
  329. no dateGuanajuato Silver · Restart of mining at VMC once a high-margin life-of-mine plan is in placegradual
  330. No dateHeron Therapeutics · Clarification of the timing of generic CINVANTI after the ruling in June 2026binary
  331. No dateHeron Therapeutics · Outcome of the review of strategic alternatives (sale, merger or refinancing)binary
  332. After the first batch (date not stated)HPQ Silicon · STAT's field evaluation (RETEX) of Novacium's prototype batteries, which could lead to larger defence ordersgradual
  333. no date from the companyHydrogenPro · Result of the strategic review (strategic investor, merger or sale)binary
  334. no date from the companyHydrogenPro · Definitive contract on two projects in the pipeline worth about NOK 300m (pending regulatory approval and technical review)binary
  335. OngoingHyperscale Data · Further Series H purchases from Ault & Company (up to USD 96m) – financing, but with dilution on conversiongradual
  336. no date from the companyInitiator Pharma · License or partner agreement for pudafensine (ED or FSD/vulvodynia)binary
  337. no dateKongsberg Automotive · Ruling on guarantee cases and insurance casebinary
  338. No dateLeclanché · Publication of the 2025 annual report and resumption of tradingbinary
  339. No dateLeclanché · Short-term financing from customers, a strategic partner or investor that can resolve the going concern questionbinary
  340. no date from the companyLifecare · Application for a pivotal CE-mark study (NOMA rejected the first application in March 2026)binary
  341. OpenMindMaze Therapeutics · Possible AI partnership and merger with Neuro.iobinary
  342. no date from the companyOcean GeoLoop · Appointment of a new CEO and completion of the sale of Ocean TuniCell to Lifecare (binding agreement 31/8-2026)gradual
  343. no date from the companyOcean GeoLoop · First pilot or customer contract for COOL (data center cooling)binary
  344. UndatedOroco Resource · Updated resource estimate and pre-feasibility study (the company only writes 'on pace')binary
  345. Not setPatagonia Gold · Feasibility study for Calcatreu and review of the Cap-Oeste underground option (mentioned as ongoing in the 2025 MD&A)binary
  346. No datePath2 Hydrogen · Delivery of a storage system to Golden Empire Transit and first projects with MP Industries in Europegradual
  347. No datePath2 Hydrogen · Exercise of the option to buy ProtonH2 (geological hydrogen), requires due diligence and shareholder approvalbinary
  348. OpenPharol · Distribution from the Rioforte bankruptcy estate on the recognised claim of EUR 897m (booked at 5.79%). Each additional percentage point in recovery equals approx. EUR 9m, approx. 12% of market cap.binary
  349. No datePhoton Energy · Publication of the revised 2025 annual report (PwC) with a possible going concern remarkbinary
  350. Not set (negotiations under way)PyroGenesis · Definitive agreements on a 1,000-ton fumed silica plant with HPQ, where PyroGenesis now owns 50% of HPQ Silica Polvere (completed 29/9-2026) and is exclusive equipment supplierbinary
  351. No dateScandinavian Medical Solutions · Appointment of a new permanent CEO after the change on 16/9-2026gradual
  352. no date from the companySenzime · First products and revenue from the OEM partnership with Philipsgradual
  353. Not disclosedSprint Bioscience · The first development milestone from Gilead on TREX1 (part of up to USD 400m)binary
  354. OngoingStenocare · Clarification of the German rules on prescribing and reimbursementbinary
  355. OngoingVerimatrix · Growth in subscription ARR (USD 16.1m, +11%), which must offset declining licences and maintenancegradual
  356. no dateViaplay · Possible joint bid from Canal+ and PPF (reported by Bloomberg in March 2026)binary
  357. No dateVistagen · FDA meeting on a new registration path for fasedienol (one phase 3 trial with LSAS as the endpoint plus PALISADE data)binary
  358. No dateVolitionRx · Publication of the Nu.Q Vet study on lymphoma in cats triggers a contractual milestone of 5m USD (manuscript in peer review since May 2026)binary
  359. no dateXCF Global · Forbearance or new payment plan with Greater Nevada Credit Union (USD 112.6m in default)binary